Glenmark Sanguine On Ichnos Capital Raise Plan Amid Mixed Dermatitis Data

Glenmark’s innovation spin-out initiates efforts to raise capital in the US, unfazed by mixed top-line results for its investigational atopic dermatitis treatment. Its parent firm has underscored the value proposition of the oncology franchise and proprietary bispecific antibody technology platform.